Cross-Sector entity
Of the tracked stories, 2 of 2 also mention C-Further, the most common co-covered peer. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each.
2 verified stories tracked
Last mentioned: Mar 15, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention C-Further, the most common co-covered peer. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each. Coya Therapeutics appears in 2 tracked Cross-Sector stories from March 15, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Coya Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Earnings Release
Expected date for Q4 and full-year 2025 financial results and clinical updates.
MiNK Collaboration
MiNK Therapeutics announces partnership with C-Further for pediatric cancer therapies, stock rises 60%.
Coya Therapeutics and MiNK Therapeutics are scheduled to report quarterly financial results this Tuesday, with investors focused on cash runway and clinical progress. These updates come at a critical juncture for both companies as they advance novel cell therapies for neurodegeneration and oncology, respectively.
Coya Therapeutics and MiNK Therapeutics are scheduled to release quarterly financial results this Tuesday, providing critical updates on their clinical pipelines and cash runways. Investors are closely monitoring MiNK's recent pediatric cancer collaboration and Coya's progress in neurodegenerative Treg therapies.
Source: themarketsdaily.com · themarketsdaily.com
